Fig. 2d-Lysis

PBMCs from healthy donors were incubated with 51chromium-loaded A549 cells naturally expressing MICA *001:12/*004 and MICB *002/*007 or Raji-MICA*001 in the presence of a range of doses of MICAB1 Fc-engineered or isotype control, cetuximab or rituximab. Upper panels: MFI of mAb binding at the cell surface revealed with a secondary Ab. Lower panels: After four hours, 51chromium levels were determined in the supernatants. The data shown are representative of three independent experiments.